Associate Professor, Medicine, University of Florida College of Medicine
Oncology
Dr. David N. Reisman, MD
|
|
Give Review
David Reisman practices Oncology. David N. Reisman is also a published physician. He has 50 paper published. The most recent paper is: A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells. David Reisman is registered with Medicare and accepts Medicare payments.
Publications
- HOXB7 promotes Malignant progression by activating the TGF-β signaling pathway.
- A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1-Letter.
- Flavonoids from Each of the Six Structural Groups Reactivate BRM, A Possible Co-factor for the Anti-Cancer Effects of Flavonoids.
- The silencing of the SWI/SNF subunit and antiCancer gene BRM in Rhabdoid tumors.
- The bidirectional p53-Wrap53β promoter is controlled by common cis- and trans-regulatory elements.
- Identifying targets for the restoration and reactivation of BRM.
- Cytoplasmic mislocalization of overexpressed FOXF1 is associated with the malignancy and metastasis of coloRectal adenocarcinomas.
- Rapid Liver enlargement and hepatic failure secondary to radiographic occult tumor invasion: two case reports and review of the literature.
- The expression of the SWI/SNF ATPase subunits BRG1 and BRM in normal human tissues.
- Loss of BRG1/BRM in human lung Cancer cell lines and primary lung Cancers: correlation with poor prognosis.
- Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling.
- Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.
- Cloning and characterization of murine p53 upstream sequences reveals additional positive transcriptional regulatory elements.
- Inducible expression of Mad accelerates growth arrest of serum deprived human glioblastoma Cells.
- Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma Cells.
- Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1.
- Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the Cell cycle.
- Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
- Nuclear factor-1 (NF-1) binds to multiple sites within the transcriptional enhancer of Moloney murine Leukemia virus.
- Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
- Positive and negative regulatory elements in the murine p53 promoter.
- Two promoters that map to 5''-sequences of the human p53 gene are differentially regulated during terminal differentiation of human myeloid leukemic Cells.
- Transforming growth factor-beta 1 inhibits cyclin D1 expression in intestinal epithelial Cells.
- ChIP (chromatin immunoprecipitation) Analysis demonstrates co-ordinated binding of two transcription factors to the promoter of the p53 tumour-suppressor gene.
- c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.
- A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid Leukemia cells.
- Surgical resection for metastatic non-small cell lung Cancer to the pancreas.
- Glucocorticoid regulation of cyclin D3 gene transcription and mRNA stability in lymphoid Cells.
- C/EBPbeta participates in regulating transcription of the p53 gene in response to mitogen stimulation.
- Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere.
- Aberrant DNA methylation of OLIG1, a novel prognostic factor in non-small cell lung Cancer.
- Transcriptional regulation of the p53 tumor suppressor gene: a potential target for Cancer therapeutics?
- Glucocorticoid regulation of G1 cyclin-dependent kinase genes in lymphoid Cells.
- Pharmacologic reversal of epigenetic silencing of the antiCancer protein BRM: a novel targeted treatment strategy.
- Inhibition of Cell growth mediated by plasmids encoding p53 anti-sense.
- Compromised HOXA5 function can limit p53 expression in human Breast tumours.
- RBP-Jkappa binds to and represses transcription of the p53 tumor suppressor gene.
- The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene.
- Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some Tumors.
- Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter.
- Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53.
- Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung Cancer risk.
- The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
- The SWI/SNF complex and Cancer.
- Targeted knockout of BRG1 potentiates lung Cancer development.
- Characterization of SWI/SNF protein expression in human breast Cancer cell lines and other malignancies.
- The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a.
- Re-expression of hSNF5/INI1/BAF47 in pediatric tumor Cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.
- Concomitant down-regulation of BRM and BRG1 in human tumor Cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.
Schools
University of Texas At Galveston Medical Branch
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of North Carolina Hospitals -
University of Texas Medical Branch Hospitals -
University of Texas Medical Branch
Hospital
-
UF Health Shands Hospital
Drug Facts
| NPI NUMBER | 1285710152 | |
| NPPES Provider LastName | REISMAN | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 326103003 | |
| NPPES Provider State | FL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 223.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 28.0 | |
| Percent Opioid Claims | 12.56 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285710152 |
| Last Name Of The Provider | REISMAN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
Dr. Peter I. Acs, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Wingard, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Stephen P. Staal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carmen J. Allegra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Duff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Coy D. Heldermon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priya K. Gopalan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Farrugia, MD
This Doctor is OpenDoctor Recommended.
|